Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1975 2
1982 1
1984 1
1985 2
1986 6
1987 6
1988 5
1989 13
1990 7
1992 17
1993 9
1994 19
1995 12
1996 16
1997 19
1998 28
1999 33
2000 30
2001 23
2002 22
2003 32
2004 25
2005 39
2006 50
2007 50
2008 37
2009 31
2010 47
2011 51
2012 43
2013 46
2014 39
2015 49
2016 47
2017 51
2018 40
2019 41
2020 28
2021 41
2022 41
2023 34
2024 39
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,072 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Yamazaki K, et al. Among authors: seki n. Ann Oncol. 2016 Aug;27(8):1539-46. doi: 10.1093/annonc/mdw206. Epub 2016 May 13. Ann Oncol. 2016. PMID: 27177863 Free article. Clinical Trial.
Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19.
Maeda R, Seki N, Uwamino Y, Wakui M, Nakagama Y, Kido Y, Sasai M, Taira S, Toriu N, Yamamoto M, Matsuura Y, Uchiyama J, Yamaguchi G, Hirakawa M, Kim YG, Mishima M, Yanagita M, Suematsu M, Sugiura Y. Maeda R, et al. Among authors: seki n. Nat Commun. 2023 Dec 20;14(1):8469. doi: 10.1038/s41467-023-44266-z. Nat Commun. 2023. PMID: 38123556 Free PMC article.
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: seki n. Curr Oncol. 2024 Feb 3;31(2):862-871. doi: 10.3390/curroncol31020064. Curr Oncol. 2024. PMID: 38392058 Free PMC article.
[microRNA].
Kojima S, Seki N. Kojima S, et al. Among authors: seki n. Nihon Rinsho. 2016 May 20;74 Suppl 3:201-4. Nihon Rinsho. 2016. PMID: 27344729 Japanese. No abstract available.
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL).
Nogami N, Kubo T, Bessho A, Sakugawa M, Ikeo S, Yokoyama T, Seki N, Ochiai R, Fujimoto N, Murakami S, Kaira K, Harada T, Kishino D, Takiguchi Y, Shimokawa T, Kiura K, Yamashita N, Okamoto H. Nogami N, et al. Among authors: seki n. Jpn J Clin Oncol. 2024 Jul 7;54(7):805-812. doi: 10.1093/jjco/hyae044. Jpn J Clin Oncol. 2024. PMID: 38594880 Free PMC article. Clinical Trial.
Human tumor rejection antigens MAGE.
Itoh K, Hayashi A, Nakao M, Hoshino T, Seki N, Shichijo S. Itoh K, et al. Among authors: seki n. J Biochem. 1996 Mar;119(3):385-90. doi: 10.1093/oxfordjournals.jbchem.a021252. J Biochem. 1996. PMID: 8830028 Free article. Review.
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
Murata Y, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Takeshita M, Ito K, Okamoto T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N. Murata Y, et al. Among authors: seki n. JTO Clin Res Rep. 2023 Oct 20;4(12):100593. doi: 10.1016/j.jtocrr.2023.100593. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046378 Free PMC article.
1,072 results